201 related articles for article (PubMed ID: 20663481)
1. The tuberculosis structural genomics consortium: a structural genomics approach to drug discovery.
Musa TL; Ioerger TR; Sacchettini JC
Adv Protein Chem Struct Biol; 2009; 77():41-76. PubMed ID: 20663481
[TBL] [Abstract][Full Text] [Related]
2. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
Ioerger TR; Sacchettini JC
Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
5. The potential impact of structural genomics on tuberculosis drug discovery.
Arcus VL; Lott JS; Johnston JM; Baker EN
Drug Discov Today; 2006 Jan; 11(1-2):28-34. PubMed ID: 16478688
[TBL] [Abstract][Full Text] [Related]
6. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
7. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
[TBL] [Abstract][Full Text] [Related]
8. High-throughput crystallography at an affordable cost: the TB Structural Genomics Consortium Crystallization Facility.
Rupp B
Acc Chem Res; 2003 Mar; 36(3):173-81. PubMed ID: 12641474
[TBL] [Abstract][Full Text] [Related]
9. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
Lou Z; Zhang X
Protein Cell; 2010 May; 1(5):435-42. PubMed ID: 21203958
[TBL] [Abstract][Full Text] [Related]
10. Drug discovery in tuberculosis: a molecular approach.
Mitra PP
Indian J Tuberc; 2012 Oct; 59(4):194-206. PubMed ID: 23342539
[TBL] [Abstract][Full Text] [Related]
11. Advances in Mycobacterium tuberculosis structural genomics: investigating potential chinks in the armor of a deadly pathogen.
Chim N; McMath LM; Beeby M; Goulding CW
Infect Disord Drug Targets; 2009 Nov; 9(5):475-92. PubMed ID: 19594421
[TBL] [Abstract][Full Text] [Related]
12. Structural genomics of Mycobacterium tuberculosis: a preliminary report of progress at UCLA.
Goulding CW; Perry LJ; Anderson D; Sawaya MR; Cascio D; Apostol MI; Chan S; Parseghian A; Wang SS; Wu Y; Cassano V; Gill HS; Eisenberg D
Biophys Chem; 2003 Sep; 105(2-3):361-70. PubMed ID: 14499904
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterium tuberculosis: a model system for structural genomics.
Smith CV; Sacchettini JC
Curr Opin Struct Biol; 2003 Dec; 13(6):658-64. PubMed ID: 14675542
[TBL] [Abstract][Full Text] [Related]
14. The TB structural genomics consortium: providing a structural foundation for drug discovery.
Goulding CW; Apostol M; Anderson DH; Gill HS; Smith CV; Kuo MR; Yang JK; Waldo GS; Suh SW; Chauhan R; Kale A; Bachhawat N; Mande SC; Johnston JM; Lott JS; Baker EN; Arcus VL; Leys D; McLean KJ; Munro AW; Berendzen J; Sharma V; Park MS; Eisenberg D; Sacchettini J; Alber T; Rupp B; Jacobs W; Terwilliger TC
Curr Drug Targets Infect Disord; 2002 Jun; 2(2):121-41. PubMed ID: 12462144
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.
Almeida Da Silva PE; Palomino JC
J Antimicrob Chemother; 2011 Jul; 66(7):1417-30. PubMed ID: 21558086
[TBL] [Abstract][Full Text] [Related]
16. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
17. Extensively drug-resistant tuberculosis: current challenges and threats.
Jain A; Mondal R
FEMS Immunol Med Microbiol; 2008 Jul; 53(2):145-50. PubMed ID: 18479439
[TBL] [Abstract][Full Text] [Related]
18. An
Kumar S; Sahu P; Jena L
Int J Mycobacteriol; 2019; 8(3):252-261. PubMed ID: 31512601
[TBL] [Abstract][Full Text] [Related]
19. New tuberculosis drugs on the horizon.
Cole ST; Riccardi G
Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
[TBL] [Abstract][Full Text] [Related]
20. Structural Annotation of the Mycobacterium tuberculosis Proteome.
Chandra N; Sandhya S; Anand P
Microbiol Spectr; 2014 Apr; 2(2):. PubMed ID: 26105824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
